We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arix Bioscience Plc | LSE:ARIX | London | Ordinary Share | GB00BD045071 | ORD 0.001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 142.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Arix Bioscience PLC (ARIX) Notice of Results and Investor Presentation 14-Sep-2023 / 07:01 GMT/BST =---------------------------------------------------------------------------------------------------------------------- Arix Bioscience plc Notice of Results and Investor Presentation LONDON, 14 September 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, will announce its results for the six months ended 30 June 2023 and provide an update on the Company's strategic review on Wednesday 27 September 2023. Analyst Briefing: 9:00am BST, Wednesday 27 September 2023 Management will host a virtual briefing for Analysts at 9:00am BST on Wednesday 27 September 2023. Analysts wishing to join should register their interest by contacting Powerscourt on arix@powerscourt-group.com or on +44 (0) 20 7290 1050. Investor Presentation: 1:00pm BST, Wednesday 27 September 2023 Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 1:00pm BST on Wednesday 27 September 2023. The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard or at any time during the live presentation via the "Ask a Question" function. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/arix-bioscience-plc/ register-investor Investors who already follow Arix on the Investor Meet Company platform will automatically receive an invitation to the event. [ENDS] Enquiries For more information on Arix, please contact: Arix Bioscience plc +44 (0)20 7290 1050 ir@arixbioscience.com Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson +44 (0)20 7250 1446 arix@powerscourt-group.com About Arix Bioscience plc Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com =---------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- ISIN: GB00BD045071 Category Code: NOR TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 271281 EQS News ID: 1725697 End of Announcement EQS News Service =------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1725697&application_name=news
(END) Dow Jones Newswires
September 14, 2023 02:01 ET (06:01 GMT)
1 Year Arix Bioscience Chart |
1 Month Arix Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions